Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
5 papers
Recent·Most cited
W. Xiao, A. Chan, M. R. Waarts…·R. Levine
This study identifies pDC-AML as a distinct AML subset with high RUNX1 mutations and pDC transcriptional features, suggesting CD123 targeting as a therapeutic strategy.
S. F. Cai, S. H. Chu, A. D. Goldberg…·S. A. Armstrong
This study shows that leukemia cell of origin affects apoptotic priming and sensitivity to LSD1 inhibitors, with Evi1 modulating p53 stability and activity.
L. A. Miles, R. L. Bowman, T. R. Merlinsky…·R. L. Levine
This study uses single-cell mutational profiling to analyze clonal trajectories in myeloid malignancies, revealing patterns of mutation acquisition and clonal complexity.
G. Minuesa, S. K. Albanese, A. Chow…·M. G. Kharas
This study identifies Ro 08-2750 as a small molecule that targets MSI2 RNA-binding activity, inducing differentiation, apoptosis, and reduced disease burden in AML models.
J. J. Harding, M. A. Lowery, A. H. Shih…·A. M. Intlekofer
The paper identifies isoform switching between mutant IDH1 and IDH2 as a mechanism of acquired resistance to IDH inhibitors in cancers.